buprenorphine

(redirected from Zubsolv)
Also found in: Dictionary.

buprenorphine

 [bu″prĕ-nor´fēn]
a synthetic opioid agonist-antagonist derived from thebaine, used in the form of the hydrochloride salt as an analgesic for moderate to severe pain and as an anesthesia adjunct. Administered sublingually or by intramuscular or intravenous injection.

buprenorphine

/bu·pre·nor·phine/ (bu″prĕ-nor´fēn) a synthetic opioid agonist-antagonist derived from thebaine, used as the hydrochloride salt as an analgesic and as an anesthesia adjunct.

buprenorphine

(byo͞o′prə-nôr′fēn′)
n.
A semisynthetic opioid drug, C29H41NO4, used usually in its hydrochloride form as an analgesic and, in combination with naloxone, for long-term treatment of addiction to opioids such as heroin.

buprenorphine

[bu′prĕ-nor′fēn]
a synthetic opioid agonist-antagonist derived from thebaine, used in the form of the hydrochloride salt as an analgesic for moderate to severe pain and as an anesthesia adjunct. Administered sublingually or by intramuscular or IV injection.
indications It is administered parenterally for the relief of moderate to severe pain and is used in tablet form to treat opioid dependence.
contraindication This Schedule V controlled substance is contraindicated for patients who may be opioid dependent.
adverse effects Among the reported adverse effects are respiratory depression, sedation, nausea, dizziness, vertigo, headache, vomiting, miosis, diaphoresis, and hypotension.

buprenorphine

A formulation of semi-synthetic opioid which may be superior to methadone in reducing heroin and cocaine abuse/dependence.

Adverse effects
Sedation, constipation.

buprenorphine

Addiction medicine An agent that may be superior to methadone in ↓ heroin and cocaine abuse Side effects Sedation, constipation. Cf Methadone.

buprenorphine

A powerful painkilling drug that binds to the body's opioid receptors. It acts for 6–8 hours. Brand names are Subutex, Temgesic and Transtec.

buprenorphine

an analgesic and opiate antagonist. Its analgesic effects are much greater and last much longer than those of morphine.
References in periodicals archive ?
revealed on Monday the receipt of the European Medicines Agency's (EMA) Marketing Authorisation (MA) for the novel rapidly-disintegrating treatment option Zubsolv (buprenorphine and naloxone) for opioid dependence.
Zubsolv is an advanced formulation of buprenorphine and naloxone using Orexo's unique knowledge and expertise in sublingual drug delivery.
The approval of the expanded indication for ZUBSOLV was supported by combined data from the Induction, STabilization, Adherence and Retention Trial (ISTART) (Study OX219-006) and Study OX219-007 which showed excellent results with over 90 percent of patients treated with ZUBSOLV remaining on treatment at Day 3 and using a formulation with a 30 percent lower dose of buprenorphine.
The company is commercializing its proprietary product, Zubsolv (buprenorphine and naloxone), for maintenance treatment of opioid dependence, in the United States.
Orexo AB has made changes to Zubsolv (buprenorphine and naloxone) sublingual tablet (CIII) managed care formulary position with CVS Caremark for patients suffering from opioid dependence.
Net revenues of Zubsolv for the quarter were SEK 124.
Orexo AB (STO:ORX) on Thursday announced its appeal of the decision rendered by the US District Court for the District of Delaware on 15 November 2016 regarding the validity of Orexo's US Patent No 8,940,330 protecting Zubsolv.
Description : The Commonwealth Of Massachusetts Executive Office Of Health And Human Services (eohhs) Office Of Medicaid (masshealth) Is Issuing This Request For Applications (rfa) From Manufacturers Of Buprenorphine/naloxone Drugs (buprenorphine/naloxone Tablets, Bunavail Film, Suboxone Film, And Zubsolv Tablets) To Pay Supplemental Drug Rebates Based On Claims For The Manufacturer s Buprenorphine/naloxone Drugs Submitted To Masshealth For Masshealth Members On A Fee For Service Basis.
Orexo said that the primary objective of the divestment has been to further strengthen the core focus on the continued development of the pharmaceutical business and on maximizing the commercial opportunity of Zubsolv.
Food and Drug Administration (FDA) of two higher dosage strengths of ZUBSOLV (buprenorphine/naloxone CIII sublingual tablet) for maintenance treatment of opioid dependence.
Indicated for the maintenance treatment of opioid dependence, Zubsolv (buprenorphine and naloxone, CIII) received approval from the Food and Drug Administration in July.
M2 EQUITYBITES-September 18, 2017-Orexo and Mundipharma announce CHMP positive opinion for opioid dependence treatment with Zubsolv in Europe